Acadia Appoints Board Member
This article was originally published in Scrip
Executive Summary
Acadia Pharmaceuticals Inc. has appointed Edmund P. Harrigan to its board of directors. Currently Harrigan serves on the board of directors of Karuna Pharmaceuticals Inc. Previously he was senior vice president of worldwide safety and regulatory for Pfizer and also held various executive leadership roles at the company, including head of worldwide business development, head of worldwide regulatory affairs and quality assurance, and head of neuroscience and ophthalmology. Prior to entering the pharma industry Harrigan was a practicing neurologist.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.